Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FLU/SAL inhalers for COPD carry greater pneumonia risk

Key clinical point: Study supports evidence that selected corticosteroid inhalers lower pneumonia risk in COPD patients.

Major finding: Budesonide/formoterol users had a 17% lower risk of severe pneumonia than that of fluticasone propionate/salmeterol users.

Study details: Retrospective cohort study of 42,393 COPD patients new to ICS/LABA from 2011 to 2015 using national claims data from in Taiwan.

Disclosures: The Taiwan Ministry of Science and Technology provided partial support for the study. Ting-Yu Chang, MS, and colleagues have no relationships to disclose.


Chang TY et al. CHEST. 2020;157:117-29.